A. Yovine

1.1k total citations
13 papers, 447 citations indexed

About

A. Yovine is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, A. Yovine has authored 13 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in A. Yovine's work include Lung Cancer Treatments and Mutations (6 papers), Fibroblast Growth Factor Research (3 papers) and Lung Cancer Research Studies (3 papers). A. Yovine is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Fibroblast Growth Factor Research (3 papers) and Lung Cancer Research Studies (3 papers). A. Yovine collaborates with scholars based in United States, Switzerland and Singapore. A. Yovine's co-authors include Diana Graus Porta, Michael Shi, Florence Dalenc, Stéphanie Deudon, John W. Smith, Thomas Bachelot, José Baselga, Sara A. Hurvitz, Mario Campone and Andrea Kay and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

A. Yovine

13 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Yovine United States 7 296 184 160 100 30 13 447
Arpita Desai United States 10 229 0.8× 165 0.9× 185 1.2× 116 1.2× 32 1.1× 38 451
Maoxiang Qian China 11 315 1.1× 118 0.6× 77 0.5× 93 0.9× 27 0.9× 43 516
Kiyoko Kataoka Japan 7 279 0.9× 152 0.8× 146 0.9× 60 0.6× 25 0.8× 11 368
Lauren Moran United States 5 299 1.0× 169 0.9× 178 1.1× 42 0.4× 41 1.4× 5 424
Ruixuan Geng China 12 234 0.8× 254 1.4× 196 1.2× 148 1.5× 54 1.8× 29 556
Qurish K. Mohemmad United States 5 304 1.0× 128 0.7× 121 0.8× 46 0.5× 42 1.4× 5 481
Elshad Hasanov United States 10 171 0.6× 105 0.6× 157 1.0× 109 1.1× 20 0.7× 36 323
Lingzhi Hong United States 12 213 0.7× 216 1.2× 238 1.5× 115 1.1× 34 1.1× 28 487
Sharon M. Sintich United States 6 217 0.7× 222 1.2× 134 0.8× 110 1.1× 22 0.7× 7 410
Rui Gou China 16 367 1.2× 120 0.7× 144 0.9× 248 2.5× 28 0.9× 28 547

Countries citing papers authored by A. Yovine

Since Specialization
Citations

This map shows the geographic impact of A. Yovine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Yovine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Yovine more than expected).

Fields of papers citing papers by A. Yovine

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Yovine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Yovine. The network helps show where A. Yovine may publish in the future.

Co-authorship network of co-authors of A. Yovine

This figure shows the co-authorship network connecting the top 25 collaborators of A. Yovine. A scholar is included among the top collaborators of A. Yovine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Yovine. A. Yovine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Wolf, Jürgen, Edward B. Garon, Harry J.M. Groen, et al.. (2022). 26P Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1. Annals of Oncology. 33. S42–S42. 6 indexed citations
2.
3.
Shaw, Alice T., Ranee Mehra, Enriqueta Felip, et al.. (2014). Evaluation of Ceritinib-Treated Patients (Pts) with Anaplastic Lymphoma Kinase Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc) and Brain Metastases in the Ascend-1 Study. Annals of Oncology. 25. iv455–iv455. 28 indexed citations
4.
Kim, D., Ranee Mehra, Enriqueta Felip, et al.. (2014). Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1. International Journal of Radiation Oncology*Biology*Physics. 90(5). S33–S34. 13 indexed citations
5.
Felip, Enriqueta, D. Kim, Ranee Mehra, et al.. (2014). Efficacy and Safety of Ceritinib in Patients (Pts) with Advanced Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): an Update of Ascend-1. Annals of Oncology. 25. iv456–iv456. 32 indexed citations
6.
André, Fabrice, Thomas Bachelot, Mario Campone, et al.. (2013). Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer. Clinical Cancer Research. 19(13). 3693–3702. 251 indexed citations
7.
Konecny, Gottfried E., Teodora Kolarova, Neil A. O’Brien, et al.. (2013). Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells. Molecular Cancer Therapeutics. 12(5). 632–642. 68 indexed citations
8.
9.
Galmarini, Carlos M., et al.. (2010). Elisidepsin. Drugs of the Future. 35(4). 287–287. 5 indexed citations
10.
Demetri, George D., Jean‐Yves Blay, A. Yovine, et al.. (2009). 9402 Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age. European Journal of Cancer Supplements. 7(2). 590–591. 3 indexed citations
11.
Cioffi, Angela, A. Lecesne, Jean‐Yves Blay, et al.. (2009). Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. Journal of Clinical Oncology. 27(15_suppl). e13510–e13510. 7 indexed citations
12.
Yovine, A., Paolo G. Casali, Federica Grosso, et al.. (2009). 9426 Trabectedin 3-hour infusion every 3 weeks in pre-treated advanced sarcoma patients: a compassionate-use administration experience. European Journal of Cancer Supplements. 7(2). 597–598. 1 indexed citations
13.
Alexandre, Jérôme, Éric Raymond, François Lokiec, et al.. (2004). Phase I and Pharmacokinetic Study of Irofulven Administered Weekly or Biweekly in Advanced Solid Tumor Patients. Clinical Cancer Research. 10(10). 3377–3385. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arpita Desai Breakdown of academic impact, for papers by Maoxiang Qian Breakdown of academic impact, for papers by Kiyoko Kataoka Breakdown of academic impact, for papers by Lauren Moran Breakdown of academic impact, for papers by Ruixuan Geng Breakdown of academic impact, for papers by Qurish K. Mohemmad Breakdown of academic impact, for papers by Elshad Hasanov Breakdown of academic impact, for papers by Lingzhi Hong Breakdown of academic impact, for papers by Sharon M. Sintich Breakdown of academic impact, for papers by Rui Gou
Rankless by CCL
2026